This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Arrhythmia	Potassium channel Kv11.1 (KCNH2; ERG)	<p>High throughput screening and rabbit studies identified a modulator of ERG activity that could help prevent drug-induced arrhythmias. In rabbits, pretreatment with the lead hit decreased the incidence of Tikosyn dofetilide-induced arrhythmias compared with no treatment. Next steps could include evaluating the compound in combination with other arrhythmogenic drugs.</p> <p>Tikosyn, a selective potassium channel blocker from Pfizer Inc. is marketed to maintain normal sinus rhythm in patients with atrial fibrillation and/or atrial flutter arrhythmias.</p> <p>SciBX 5(41); doi:10.1038/scibx.2012.1083 Published online Oct. 18, 2012</p>	Patent and licensing status unavailable	<p>Potet, F. <i>et al. J. Biol. Chem.</i>; published online Oct. 2, 2012; doi:10.1074/jbc.M112.380162 Contact: Sabina Kupersmidt, Vanderbilt University School of Medicine, Nashville, Tenn. e-mail: sabina.kupersmidt@vanderbilt.edu</p>